These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25388285)

  • 1. Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.
    Kadayakkara DK; Korrer MJ; Bulte JW; Levitsky HI
    Cancer Res; 2015 Jan; 75(1):51-61. PubMed ID: 25388285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.
    Long CM; van Laarhoven HW; Bulte JW; Levitsky HI
    Cancer Res; 2009 Apr; 69(7):3180-7. PubMed ID: 19276358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.
    Desbien AL; Dubois Cauwelaert N; Reed SJ; Bailor HR; Liang H; Carter D; Duthie MS; Fox CB; Reed SG; Orr MT
    J Immunol; 2016 Dec; 197(11):4351-4359. PubMed ID: 27794001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes.
    Ruiz-de-Angulo A; Zabaleta A; Gómez-Vallejo V; Llop J; Mareque-Rivas JC
    ACS Nano; 2016 Jan; 10(1):1602-18. PubMed ID: 26678549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8
    Xu X; Jin Z; Liu Y; Gong H; Sun Q; Zhang W; Zhao L
    Cancer Lett; 2019 Jan; 440-441():94-105. PubMed ID: 30352261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.
    Lambert SL; Yang CF; Liu Z; Sweetwood R; Zhao J; Cheng L; Jin H; Woo J
    PLoS One; 2012; 7(12):e51618. PubMed ID: 23284726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.
    Fox CB; Moutaftsi M; Vergara J; Desbien AL; Nana GI; Vedvick TS; Coler RN; Reed SG
    Vaccine; 2013 Dec; 31(49):5848-55. PubMed ID: 24120675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
    Davis MB; Vasquez-Dunddel D; Fu J; Albesiano E; Pardoll D; Kim YJ
    Clin Cancer Res; 2011 Jun; 17(12):3984-92. PubMed ID: 21543518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
    Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
    Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
    Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
    Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.
    Santone M; Aprea S; Wu TY; Cooke MP; Mbow ML; Valiante NM; Rush JS; Dougan S; Avalos A; Ploegh H; De Gregorio E; Buonsanti C; D'Oro U
    Hum Vaccin Immunother; 2015; 11(8):2038-50. PubMed ID: 26024409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.
    Hamdy S; Molavi O; Ma Z; Haddadi A; Alshamsan A; Gobti Z; Elhasi S; Samuel J; Lavasanifar A
    Vaccine; 2008 Sep; 26(39):5046-57. PubMed ID: 18680779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D; Krieg AM; Lubaroff DM
    Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.
    Ly LV; Sluijter M; Versluis M; Luyten GP; van Stipdonk MJ; van der Burg SH; Melief CJ; Jager MJ; van Hall T
    Cancer Res; 2010 Nov; 70(21):8339-46. PubMed ID: 20940397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
    Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
    J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.
    Desbien AL; Reed SJ; Bailor HR; Dubois Cauwelaert N; Laurance JD; Orr MT; Fox CB; Carter D; Reed SG; Duthie MS
    Eur J Immunol; 2015 Feb; 45(2):407-17. PubMed ID: 25367751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
    Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.